_0001.png)
_0003.gif)
_0007.png)
_0006.gif)
_0005.png)
Rodos BioTarget GmbH (RBT) is a privately-held, venture capital-funded biotechnology company based in Hannover, Germany.
RBT holds a novel cell-specific nanocarrier called the TargoSphere®. This Targeted Drug Delivery System addresses C-type lectin receptors (CLRs) on the surface of professional antigen-presenting cells (APCs), whitch allows for the development of potent specific immunotherapies as these most crucial immune cells of the immune system initiate antigen-specific immune responses as well as connect the innate and adaptive branches of immunity. Importantly, the TargoSphere® harnesses an evolutionarily ancient receptor family by taking advantage of CLRs whose proper biological function consists in binding and internalizing pathogens via their peculiar surface carbohydrate decoration. By the same token, the TargoSphere® enters the target cells’ endolysosomal system, which creates a broad spectrum of medical opportunities.
Depending on the respective payload, the options of this platform technology divide into two principal arms:
• To induce numerous APC-driven protective or therapeutic antigen-specific
• immune responses; and
• To eradicate cellular infectious pathogen reservoirs.
This permits a restoration of immune competence in a variety of disease states as well as innovative interventions against various infectious diseases and cancers.
RBT collaborates with partners in the biotech and pharmaceutical industries, and we also strives for enabling lifecycle management of already approved drugs and immunomodulators by employing the TargoSphere®.
RBT holds a novel cell-specific nanocarrier called the TargoSphere®. This Targeted Drug Delivery System addresses C-type lectin receptors (CLRs) on the surface of professional antigen-presenting cells (APCs), whitch allows for the development of potent specific immunotherapies as these most crucial immune cells of the immune system initiate antigen-specific immune responses as well as connect the innate and adaptive branches of immunity. Importantly, the TargoSphere® harnesses an evolutionarily ancient receptor family by taking advantage of CLRs whose proper biological function consists in binding and internalizing pathogens via their peculiar surface carbohydrate decoration. By the same token, the TargoSphere® enters the target cells’ endolysosomal system, which creates a broad spectrum of medical opportunities.
Depending on the respective payload, the options of this platform technology divide into two principal arms:
• To induce numerous APC-driven protective or therapeutic antigen-specific
• immune responses; and
• To eradicate cellular infectious pathogen reservoirs.
This permits a restoration of immune competence in a variety of disease states as well as innovative interventions against various infectious diseases and cancers.
RBT collaborates with partners in the biotech and pharmaceutical industries, and we also strives for enabling lifecycle management of already approved drugs and immunomodulators by employing the TargoSphere®.
_0025.png)
HRB 203405, Handelsregister B, Hannover • Steuer-Nr. / Tax No.: DE262938939 • UStId-Nr. / VAT No.: 25/202/41866
Latest News
May 2010: RBT receives approval on a ZIM development grant in the area of hepatitis C treatment by the BMWi (the Federal Ministry of Economy and Technology).
April 2010: RBT receives approval on a grant in the area of malaria vaccination by the Frontier Program of the University of Heidelberg’s Cluster of Excellence.
April 2010: RBT receives approval on a grant in the area of malaria vaccination by the Frontier Program of the University of Heidelberg’s Cluster of Excellence.
Meet Rodos BioTarget
October 29 to November 2, 2010: RBT presents at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA, USA, on “Low serum vitamin D in NASH patients and antifibrogenic properties of vitamin D in vitro: Implications for NASH.”
July 6, 2010: RBT is invited to present in the 9th Seed4Money Investment Forum in Frankfurt/Main.
June 14-15, 2010: RBT receives sponsorship to present its technology platform for lifecycle management at the General Assembly of the BPI (the German Association of the Pharmaceutical Industry) in Berlin, Germany.
“C-Type lectin-targeted Nanocarriers for Specifically Addressing and Priming Dendritic Cells”.
May 20, 2010: RBT is nominated “Next Wave Company” at the Bio€quity EUROPE 2010 in Zurich, Switzerland.
April 27, 2010: RBT participates in the High-Tech Partnering Conference 2010 in Bonn, Germany.
April 21 to 22, 2010: Dr. Furch presents at the Deutsche Biotechnologietage 2010 in Berlin, Germany, on “TargoSpheres®: Enabling Technology for Targeted Drug Delivery and Vaccination”.
April 28 to 29, 2010: RBT is selected to join the pool of presenting high-tech companies at the German Equity Forum Spring 2010 (Deutsches Eigenkapital Forum Frühjahr 2010) in Dresden, organized by kfw (German Development Bank)
March 15-17, 2010: RBT participates in the Charité Entrepreneurship Summit in Berlin, Germany, hosted by the Stiftung Charité (Charité Foundation).
March 8-10, 2010: RBT participates at the BIO Europe Spring 2010 partnering conference in Barcelona.
December 1, 2009: Dr. Furch is invited by the European Commission and ebe (European Biopharmaceutical Enterprises) to discuss at the “Industry Workshop on Access to Finance for Small and Medium-sized Biopharmaceutical Companies in Europe” in Brussels.
November 1-4, 2009: RBT participates at the BIO Europe 2009 partnering conference in Vienna.
July 6, 2010: RBT is invited to present in the 9th Seed4Money Investment Forum in Frankfurt/Main.
June 14-15, 2010: RBT receives sponsorship to present its technology platform for lifecycle management at the General Assembly of the BPI (the German Association of the Pharmaceutical Industry) in Berlin, Germany.
“C-Type lectin-targeted Nanocarriers for Specifically Addressing and Priming Dendritic Cells”.
May 20, 2010: RBT is nominated “Next Wave Company” at the Bio€quity EUROPE 2010 in Zurich, Switzerland.
April 27, 2010: RBT participates in the High-Tech Partnering Conference 2010 in Bonn, Germany.
April 21 to 22, 2010: Dr. Furch presents at the Deutsche Biotechnologietage 2010 in Berlin, Germany, on “TargoSpheres®: Enabling Technology for Targeted Drug Delivery and Vaccination”.
April 28 to 29, 2010: RBT is selected to join the pool of presenting high-tech companies at the German Equity Forum Spring 2010 (Deutsches Eigenkapital Forum Frühjahr 2010) in Dresden, organized by kfw (German Development Bank)
March 15-17, 2010: RBT participates in the Charité Entrepreneurship Summit in Berlin, Germany, hosted by the Stiftung Charité (Charité Foundation).
March 8-10, 2010: RBT participates at the BIO Europe Spring 2010 partnering conference in Barcelona.
December 1, 2009: Dr. Furch is invited by the European Commission and ebe (European Biopharmaceutical Enterprises) to discuss at the “Industry Workshop on Access to Finance for Small and Medium-sized Biopharmaceutical Companies in Europe” in Brussels.
November 1-4, 2009: RBT participates at the BIO Europe 2009 partnering conference in Vienna.
Latest Scientific Publications
|
Gieseler RK, Marquitan G, Schlattjan M, Sowa J-P, Bechmann LP, Timm J, Roggendorf M, Gerken G, Friedman SL, Canbay A. Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. J Viral Hepatol 2010: In Press. Bechmann LP, Jochum C, Kocabayoglu P, Kassalik M, Gieseler RK, Saner F, Paul A, Gerken G, Canbay A, Cytokeratin 18-based Modification of the MELD Score Improves Prediction of Spontaneous Survival after Acute Liver Injury. J Hepatol 2010: In Press. |
|
|
Associated Editorial: Samuel D, Ichai P. Prognosis indicator in acute liver failure: Is there a place for cell death markers? J Hepatol 2010: In Press. |
|
|
Dechêne A, Sowa J-P, Gieseler RK, Jochum C, Bechmann L, El Fouly A, Schlattjan M, Saner F, Baba H, Paul A, Dries V, Gerken G, Friedman SL, Canbay A. Acute Liver Failure is Associated with Elevated Liver Stiffness and Hepatic Stellate Cell Activation. Hepatology 2010, May 14: Epub. Link Bechmann LP, Gieseler RK, Sowa JP, Kahraman A, Erhard J, Wedemeyer I, Emons B, Jochum C, Feldkamp T, Gerken G, Canbay A. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int 2010, April 9: Epub. Link Kahraman A, Schlattjan M, Kocabayoglu P, Yildiz-Meziletoglu S, Schlensak M, Fingas CD, Wedemeyer I, Marquitan G, Gieseler RK, Baba HA, Gerken G, Canbay A. Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in nonalcoholic steatohepatitis. Hepatology 2010;51:92-102. Link |
|
|
Associated Editorial: Gao B. Natural killer group 2 member D, its ligands, and liver disease: good or bad? Hepatology 2010;51:8-11. Link |
|
|
Jochum C, Gieseler RK, Gawlista I, Fiedler A, Manka P, Saner FH, Roggendorf M, Gerken G, Canbay A. Hepatitis B-associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion 2009;80:235-40. Link |
|
- Home
- About us
- Research and Development
- Publications
- Partnerships
- Media
- FAQ
- Careers
- Contact